Sarcoma Treatment Guide in Improving Self-Monitoring in Patients With Sarcoma Receiving Chemotherapy
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/1/2019 |
| Start Date: | May 16, 2017 |
| End Date: | May 16, 2020 |
| Contact: | The Ohio State University Comprehensive Cancer Center |
| Email: | OSUCCCClinicaltrials@osumc.edu |
| Phone: | 800-293-5066 |
Sarcoma Treatment Guide Pilot Study
This randomized pilot clinical trial studies how well the Sarcoma Treatment Guide works in
improving self-monitoring in patients with sarcoma who are receiving chemotherapy. The
Sarcoma Treatment Guide may help patients with sarcoma to be better informed, become more
engaged with care, encourage communication, and to better manage side effects associated with
chemotherapy treatments in order to improve quality of life.
improving self-monitoring in patients with sarcoma who are receiving chemotherapy. The
Sarcoma Treatment Guide may help patients with sarcoma to be better informed, become more
engaged with care, encourage communication, and to better manage side effects associated with
chemotherapy treatments in order to improve quality of life.
PRIMARY OBJECTIVES:
I. To evaluate whether symptom management and communication are improved in patients who are
chemotherapy naive who receive a Sarcoma Treatment Guide as compared to those that have not.
SECONDARY OBJECTIVES:
I. To explore whether patients who have previously undergone chemotherapy benefit from a
Sarcoma Treatment Guide (STG) in regard to symptom management and have improved communication
between patient and providers.
II. To assess patient satisfaction with using the STG at the end of the trial.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive the STG before completing 4 courses of standard of care chemotherapy.
ARM B: Patients complete 2 courses of standard of care chemotherapy and then receive the STG
before completing 2 additional courses of standard of care chemotherapy.
I. To evaluate whether symptom management and communication are improved in patients who are
chemotherapy naive who receive a Sarcoma Treatment Guide as compared to those that have not.
SECONDARY OBJECTIVES:
I. To explore whether patients who have previously undergone chemotherapy benefit from a
Sarcoma Treatment Guide (STG) in regard to symptom management and have improved communication
between patient and providers.
II. To assess patient satisfaction with using the STG at the end of the trial.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive the STG before completing 4 courses of standard of care chemotherapy.
ARM B: Patients complete 2 courses of standard of care chemotherapy and then receive the STG
before completing 2 additional courses of standard of care chemotherapy.
Inclusion Criteria:
- Be able to read, write, and understand English
- Sarcoma clinic patient
- About to begin either oral or cytotoxic chemotherapy
Exclusion Criteria:
- Received previous chemotherapy
We found this trial at
1
site
Columbus, Ohio 43210
Principal Investigator: James L. Chen, MD
Phone: 614-293-0463
Click here to add this to my saved trials
